Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.

@article{Keystone2011RapidII,
  title={Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.},
  author={Edward Clark Keystone and Jeffrey R. Curtis and Roy M Fleischmann and Daniel e. Furst and Dinesh Khanna and Josef S Smolen and Philip J Mease and Michael H. Schiff and Geoffroy Coteur and Owen R Davies and Bernard G Combe},
  journal={The Journal of rheumatology},
  year={2011},
  volume={38 6},
  pages={990-6}
}
OBJECTIVE To assess the kinetics of response to certolizumab pegol (CZP), and association between rapid response and longterm outcomes, in patients with active rheumatoid arthritis (RA). METHODS This was a post-hoc analysis of the randomized, double-blind RAPID 1 study in patients who received methotrexate (MTX) and either CZP 200 mg subcutaneously or placebo every 2 weeks for 52 weeks. Clinical and radiographic outcomes at Week 52 were evaluated based on the Disease Activity Score 28 (DAS28… CONTINUE READING